Literature DB >> 2551303

Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes.

A Wildfeuer1, H Laufen, D Müller-Wening, O Haferkamp.   

Abstract

14C-labeled azithromycin, a new macrolide antibiotic, was accumulated by various phagocytic cells isolated from volunteers or patients. The concentration of the antibiotic in monocytes, polymorphonuclear leucocytes (PMNLs), and alveolar macrophages was greater than that in the surrounding medium by a factor of between 200 and 668. Azithromycin penetrated somewhat more rapidly into PMNLs and monocytes than into alveolar macrophages. On the other hand the final concentration in the alveolar macrophages was greater by a factor of about 3 than that in the other two phagocytic cells. Staphylococcus aureus, Legionella pneumophila and Haemophilus influenzae previously taken up by the phagocytes were rapidly inactivated by low (0.031-0.5 micrograms/ml) concentrations of the antibiotic, which in the presence of the cells were subinhibitory. There is thus a clear synergism between azithromycin and the phagocytic cells which leads to increased intracellular killing of the bacteria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551303

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  21 in total

1.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 2.  The activity of azithromycin in animal models of infection.

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Phagocyte uptake and transport of azithromycin.

Authors:  P J McDonald; H Pruul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Authors:  S Schönwald; V Skerk; I Petricevic; V Car; L Majerus-Misic; M Gunjaca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

6.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.

Authors:  H Levert; B Gressier; I Moutard; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.